Goldline Pharmaceuticals' immediate term goal to clock a group turnover as envisaged in the financial year 2024-25 has been successfully achieved. We have ploughed back investments from our net profit to spread out operations in most of the geographical areas of India adding innovative formulations and keeping the top line accentuate and holding on the bottom line manageable with increasing overhead expenditures incurred in such a move. We are aiming to touch a level almost 20% growth over the previous financial year with 200+ products for which we have all indications of achieving the earmark as distinctively predictable.

In the medium and long term horizons of our business aims to make presence in other specialty therapeutic segments and make cellular strategic business units as profit centre to manage costs better and make operations professional and more squarely remunerative.

The organization is already in the process of setting up of fully owned state-of-the-art production facility and looking at drastically lessening the third party manufacturing obligations in terms of pricing and supplies. All these business approaches take care of all micro and macro economic factors at various levels including asset capitalization. Though all such factors may individually look small but collectively they are highly impacting on both top line and bottom lines of the business operation resulting into higher profitability which can collectively boost every ones interests.